Selegiline: Current perspectives on issues related to neuroprotection and mortality

Neurology

Volumn 47, Issue 6 SUPPL. 3, 1996, Pages

  Olanow, C Warren ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING); CARBIDOPA PLUS LEVODOPA; SELEGILINE; TOCOPHEROL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA;

EID: 0029731656     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.47.6_suppl_3.210s     Document Type: Review

References (72)

1. Knoll J, Esceri Z, Kelemen K, et al. Phenyliopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 1965;155:154-164.
2. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the "cheese effect." Psychopharmacology 1978;57:33-38.
3. Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side-effects of (-)deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989;46:45-50.
4. Mendis N, Paire CMB, Sandler M, et al. Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to elevate depression related to freedom from the cheese effect? Psychopharmacology (Berlin) 1981;73:87-90.
5. Knoll J. The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J Neural Transm 1978;43:177-198.
6. Birkmayer W, Riederer P, Youdim MBH, Linauer W. The potentiation of the antiakinetic effect after L-dopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975; 36:303-326.
7. Lees AJ, Kohent LJ, Shaw KM, et al. Deprenyl in Parkinson's disease. Lancet 1977;2:791-795.
8. Eisler T, Teravainen HT, Nelson R, et al. Clinical and biochemical effects of (-)deprenyl in patients with Parkinson's disease: clinical aspects. Neurology 1981;31:19-23.
9. Stern GM, Lees AJ, Hardie RJ, Sandler M. Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease. Acta Neurol Scand 1983;68:113-116.
10. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988;11:45-55.
11. Lees AJ on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-1606.
12. Langston JW, Ballard PA, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 1983;219:979-980.
13. Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Comm 1984;120:457-478.
14. +. Neurosci Lett 1987;75:323-328.
15. Singer TP, Castagnoli N Jr, Ramsay RR, Trevor AJ. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 1987;49:1-8.
16. Cohen G, Pasik P, Cohen B, et al. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 1985;106:209-210.
17. Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984;225:1480-1482.
18. Heikkila RE, Manzino L, Duvoisin RC, Cabbat FS. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidase inhibitors. Nature 1984;311:467-469.
19. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40:32-37.
20. Jenner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992;42:2241-2250.
21. Olanow CW, Cohen G, Perl DP, Marsden CD, eds. Role of iron and oxidant stress in the normal and parkinsonian brain. Ann Neurol 1992;32(suppl)S1-S145.
22. Jenner P, Olanow CW. Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders. In: Olanow CW, Jenner P, Youdim MHB, eds. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press, 1996:24-45.
23. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245:519-522.
24. Parkinson's Study Group. DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052-1060.
25. Parkinson's Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
26. Parkinson's Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
27. Olanow CW, Calne D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 1991;42:13-26.
28. Schulzer M, Mak E, Calne DB. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992;32:795-798.
29. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of signs and symptoms in Parkinson's disease. Ann Neurol 1995;38:771-777.
30. Olanow CW, Koller WC. Deprenyl in Parkinson's disease [letter]. Ann Neurol 1996;40:269.
31. Hauser RA, Olanow CW, Koller WC. Time course of wash-out of symptomatic medication in Parkinson's disease [abstract]. Neurology 1994;44:259.
32. Elizan TS, Yahr MD, Moros DA, et al. Selegiline use to prevent progression of Parkinson's disease: experience in 22 de novo patients. Arch Neurol 1989;46:1275-1279.
33. Brannan T, Yahr MD. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 1995;37:95-98.
34. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307: 469-472.
35. Parkinson's Study Group. The impact of extended deprenyl and tocopherol treatment in Parkinson's disease patients requiring levodopa. Ann Neurol 1996;39:29-36.
36. Parkinson's Study Group. The impact of extended deprenyl and tocopherol treatment in Parkinson's disease patients not requiring levodopa. Ann Neurol 1996;39:37-45.
37. Parkinson's Study Group. A controlled clinical trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Ann Neurol 1993;33:350-356.
38. Parkinson's Study Group. A controlled trial of lazabemide (RO19-6327) in levodopa treated Parkinson's disease. Arch Neurol 1994;51:342-347.
39. Parkinson's Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol 1996;40:99-107.
40. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-677.
41. Mytilineou C, Cohen G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenyl-pyridinium ion. J Neurochem 1985;45:1951-1953.
42. Roy E, Bedard PJ. L-Deprenyl increases survival of rat foetal nigral neurones in culture. Neuroreport 1993;4:1183-1186.
43. Finnegan KT, Skratt JJ, Irwin I, et al. Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 1990;184:119-126.
44. Ansari KS, Yu PH, Kruck TPA, Tatton WG. Rescue of axotomized immature rat facial motoneurons by R(!)-L-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 1993;13:4042-4053.
45. Salo PT, Tatton WG. L-Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 1992;31:394-400.
46. + in vivo. Eur J Pharmacol 1993; 243:241-247.
47. Tatton WG, Ju WYH, Wadia J, Tatton NA. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. In: Olanow CW, Jenner P, Youim, MHB, eds. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic; 1996:202-220.
48. Tatton WG, Ju WYL, Holland DP, et al. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575.
49. Carrillo M, Kanai M, Nokubo M, Kitani K. (-)Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 1990;48:517-521.
50. Carrillo M-C, Kanai S, Nokubo M, Ivy GO, Sata Y, Kitani K. (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp Neurol 1992;116:286-294.
51. Carrillo MC, Kanai S, Sato Y, Ivy GO, Kitani K. Sequential changes in activities of superoxide dismutase and catalase in brain regions and liver during (-)deprenyl infusion in male rats. Biochem Pharmacol 1992;44:2185-2189.
52. Tatton WG, Chalmers-Redman RME. Modulation of gene expression rather than monoamine oxidase inhibition: (-)deprenyl-related compounds in controlling neurodegeneration. Neurology 1996;47:S171-S183.
53. Wadia JS, Chalmers-Redman R, Ju WJH, Tatton WG. (-)-Deprenyl modifies pre-apoptotic changes in mitochondrial calcium and oxidative radicals in PC 12 cells. Neuroscience 1996 (in press).
54. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW. L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity. J Neurochem 1996 (in press).
55. Heinonen EH, Myllyla V, Sotaniemi K, et al. Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 1989;126: 93-99.
56. Mytilineou C, Radcliffe P, Olanow CW. L-(-)-desmethyl-selegiline, a metabolite of L-(-)-seleginine, protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem 1996 (in press).
57. Borbe HO, Niebch G, Nickel B. Kinetic evaluation of MAO-B activity following oral administration of selegiline and desmethyl-selegiline in rats. J Neural Transm 1990;32:131-137.
58. Knoll J. Extension of life span of rats by long-term (-)deprenyl treatment. Mt Sinai J Med 1988;55:67-74.
59. Milgram NW, Racine RJ, Nellis P, et al. Maintenance of L-deprenyl prolongs life in aged male rats. Life Sci 1990;47: 415-420.
60. Kitani K, Kanai S, Sato Y, et al. Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats: further evidence. Life Sci 1993;52:281-288.
61. Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of L-deprenyl to Modopar treatment of Parkinson's disease: a long-term study. J Neural Transm 1985;64:113-127.
62. Olanow CW, Godbold J, Koller WC. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. BMJ 1996;312: 702-703.
63. Maki-Ikola O, Kilkku O, Heinonen E. Other studies have not shown increased mortality. BMJ 1996;312:702.
64. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality: a point of view. Ann Neurol 1996 (in press).
65. Silva MT, Watts PM, Jenner P. Parkinson's disease is rarely a primary cause of death [letter]. BMJ 1996;312:703.
66. Jellinger KA. Causes of death need confirmation [letter]. BMJ 1996;312:704.
67. Gerlach M, Riederer P, Vogt H. "On-treatment" rather than intention to treat analysis should have been used [letter]. BMJ 1996;312:704.
68. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556.
69. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential trials. Control Clin Trials 1984;5:348-361.
70. Haybittle JL. Repeated assessments of results in clinical trials of cancer treatment. Br J Radiol 1971;44:793-797.
71. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977;64:191-199.
72. Tsiatis AA, Rosner GL, Mehta CR. Exact confidence intervals following a group sequential test. Biometrics 1984;40:797-803.